Sandra Ciesek
Overview
Explore the profile of Sandra Ciesek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
5914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grikscheit K, Berger A, Rabenau H, Kohmer N, Appel K, Scherer M, et al.
Emerg Microbes Infect
. 2025 Jan;
14(1):2459137.
PMID: 39868965
Viremia defined as detectable SARS-CoV-2 RNA in the blood is a potential marker of disease severity and prognosis in COVID-19 patients. Here, we determined the frequency of viremia in serum...
2.
Lampertico P, Bogomolov P, Chulanov V, Stepanova T, Morozov V, Allweiss L, et al.
Liver Int
. 2025 Jan;
45(2):e70008.
PMID: 39853842
Background And Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic...
3.
Kramer A, Seifert J, Abele-Horn M, Arvand M, Biever P, Blacky A, et al.
GMS Hyg Infect Control
. 2024 Oct;
19:Doc42.
PMID: 39391860
The consensus-based guideline "hand antisepsis and hand hygiene" for Germany has the following sections: Prevention of nosocomial infections by hygienic hand antisepsis, prevention of surgical site infections by surgical hand...
4.
Metzdorf K, Jacobsen H, Kim Y, Teixeira Alves L, Kulkarni U, Cokaric Brdovcak M, et al.
Front Immunol
. 2024 Aug;
15:1383086.
PMID: 39119342
Current vaccines against COVID-19 elicit immune responses that are overall strong but wane rapidly. As a consequence, the necessary booster shots have contributed to vaccine fatigue. Hence, vaccines that would...
5.
Scheithauer S, Hoffmann J, Lang C, Fenz D, Berens M, Koster A, et al.
Gesundheitswesen
. 2024 Jul;
PMID: 39009032
Während einer Pandemie muss Resilienz nicht nur als Eigenschaft des Gesundheitssystems, sondern auch des umgebenden Forschungsumfelds betrachtet werden. Um verlässliche, evidenzbasierte Empfehlungen aus der Universitätsmedizin an die Gesundheitspolitik und die...
6.
Barnbrock A, Berger A, Lauten M, Demmert M, Klusmann J, Ciesek S, et al.
Sci Rep
. 2024 Jun;
14(1):14867.
PMID: 38937530
In contrast to transplant recipients, there is a paucity of data regarding frequency and clinical significance of viraemia in children receiving conventional chemotherapy. In a prospective observational study, we assessed...
7.
Qu B, Miskey C, Gomer A, Kleinert R, Ibanez S, Eberle R, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(23):e2407437121.
PMID: 38814864
The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes...
8.
Groh A, Vehreschild M, Diaz D, Kuchta A, Dodoo C, Alvarado L, et al.
Sci Rep
. 2024 May;
14(1):12365.
PMID: 38811590
SARS-CoV-2 is the causative agent of COVID-19. Timely and accurate diagnostic testing is vital to contain the spread of infection, reduce delays in treatment and care, and inform patient management....
9.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
J Hepatol
. 2024 May;
81(4):621-629.
PMID: 38734383
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week...
10.
Thummler L, Beckmann N, Sehl C, Soddemann M, Brass P, Bormann M, et al.
Viruses
. 2024 Apr;
16(4).
PMID: 38675888
The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries...